Molecular therapeutic strategies targeting Duchenne muscular dystrophy

Journal of Child Neurology

Volumn 25, Issue 9, 2010, Pages 1145-1148

  Mendell, Jerry R ^a   Rodino Klapac, Louise R ^a   Malik, Vinod ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Duchenne muscular dystrophy; exon skipping; gene therapy; mutation suppression

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATALUREN; CORTICOSTEROID; DYSTROPHIN; GENTAMICIN;

CLIMBING; CLINICAL TRIAL; CODON; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; FORCED VITAL CAPACITY; GENE REPLACEMENT THERAPY; GENETIC ANALYSIS; HUMAN; MOLECULAR THERAPY; MUSCLE BIOPSY; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; TREATMENT OUTCOME; WALKING;

CHILD; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION;

EID: 77956300673     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073810371005     Document Type: Short Survey

References (33)

1. Koenig MEP, Hoffman CJ, Bertelson AP, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987 ; 50: 509-517.
2. Hoffman EP, Brown RH Jr, Kunkel LM Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987 ; 51: 919-928.
3. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 ; 320: 1592-1597.
4. Manzur AY, Kuntzer T., Pike M., Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004 ; (2). CD003725.
5. King WM, Ruttencutter R., Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007 ; 68: 1607-1613.
6. Biggar WD, Gringas M., Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001 ; 138: 45-50.
7. Connolly AM, Schierbecker J., Renna R., Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2002 ; 12: 917-925.
8. Linden RM, Berns KI Molecular biology of adeno-associated viruses. Contrib Microbiol. 2000 ; 468-484.
9. Gao G., Vandenberghe LH, Wilson JM New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005 ; 5: 285-297.
10. Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet. 1995 ; 4: 1251-1258.
11. Harper SQ, Hauser MA, DelloRusso C., et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002 ; 8: 253-261.
12. Scott JM, Li S., Harper SQ, et al. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul Disord. 2002 ;(suppl 11). S23 - S29.
13. Gregorevic P., Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004 ; 10: 828-834.
14. Wang B., Li J., Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A. 2000 ; 97: 13714-13719.
15. Watchko J., O'Day T., Wang B., et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther. 2002 ; 13: 1451-1460.
16. Mendell JR, Campbell K., Rodino-Klapac L., Immunity to Dystrophin Revealed by Gene Therapy for Duchenne Muscular Dystrophy. N Engl J Med. In press.
17. Mendell JR, Buzin CH, Feng J., et al. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology. 2001 ; 57: 645-650.
18. Flanigan KM, von Niederhausern A., Dunn DM, et al. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet. 2003 ; 72: 931-939.
19. Kaufman RJ Correction of genetic disease by making sense from nonsense. J Clin Invest. 1999 ; 104: 367-368.
20. Anderson WF, Gorini L., Breckenridge L. Role of ribosomes in streptomycin-activated suppression. Proc Natl Acad Sci U S A. 1965 ; 54: 1076-1083.
21. Davies J., Gilbert W., Gorini L. Streptomycin, suppression, and the code. Proc Natl Acad Sci U S A. 1964 ; 51: 883-890.
22. Barton-Davis ER, Cordier L., Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999 ; 104: 375-381.
23. Wagner KR, Hamed S., Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol. 2001 ; 49: 706-711.
24. Politano L., Nigro G., Nigro V., et al. Gentamicin administration in Duchenne patients with premature stop codon: preliminary results. Acta Myol. 2003 ; 22: 15-21.
25. Malik V., Rodino-Klapac LR, Viollet L., et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol. Epub ahead of print, March 15, 2010.
26. Hamed SA Drug evaluation: PTC-124-a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs. 2006 ; 9: 783-789.
27. Hirawat S., Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007 ; 47: 430-444.
28. van Deutekom JC, Bremmer-Bout M., Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001 ; 10: 1547-1554.
29. Takeshima Y., Wada H., Yagi M., et al. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev. 2001 ; 23: 788-790.
30. Aartsma-Rus A., Janson AA, Kaman WE, et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet. 2003 ; 12: 907-914.
31. McClorey G., Moulton HM, Iversen PL Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 2006 ; 13: 1373-1381.
32. van Deutekom JC, Janson AA, Ginjaar LB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007 ; 357: 2677-2686.
33. Kinalia M., Arechavala-Gomeza V., Feng L., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009 ; 8: 918-928.